The present invention relates to a degradable intrauterine system for the prolonged release of an active ingredient in the uterine cavity comprising (a) a degradable A and B block copolymer, wherein the A block is a polyester, the B block is a poly (oxyethylene) (PEO) with a weight-average molecular weight of greater than or equal to 50 kDa; and the ethylene oxide unit/ester unit molar ratio is between 0.05 and 5; (b) at least one polyester homopolymer; and (c) at least one active ingredient intended to be released in the uterine cavity. The invention also relates to a kit comprising at least one intrauterine system according to the invention and means for inserting the system into the uterine cavity.

An elastic sheet for re-activating an endometrial basal layer in a uterine cavity comprises a silicone rubber and a drug, wherein the drug is encased inside the silicone rubber in the manner of a drug storage zone, or uniformly dispersed inside the silicone rubber, or carried by an outer surface of the silicone rubber as a coating, and the drug comprises an estrogen. A method for forming the elastic sheet with a drug in a matrix-type elastic sheet; or as a sustained release coating is provided. The estrogen is loaded on the silicone rubber, and thus the endometrial basal layer is continuously activated through drug stimulation, allowing for the endometrial basal layer to re-proliferate the functional layers, thereby restoring the normal endometrial structure and completely preventing adhesions.

The invention relates to a method for altering the release characteristics of a long acting drug delivery device containing at least two drugs in different segments, wherein the segments are arranged to a specific sequence.

The invention furthermore relates to a drug delivery device with reduced initial burst containing two different drugs in different segments.

The invention further relates to a delivery device manufactured according to the a.m. method and its use in contraception and gynecological therapies.

Ligands of complement receptor 3, including ligands of the I domain of the alpha subunit of this receptor, are useful in methods, compositions and articles/devices for inhibiting the interaction of pathogens to a complement receptor 3-expressing cell and for treating or inhibiting the development of infections caused by such pathogens.